Bioverge Ventures

Have you missed it? At #Hepatx, we have entered into a license agreement with Mayo Clinic Ventures to advance HepaTx’s innovative stem cell technology into clinical trials! 👏 🤯 Read the PR below 👇 https://lnkd.in/efTx3vpA #liver #liverhealth #celltherapy #technology #patients #research #regenerativemedicine #hepatology #collaboration

Ancilia is incredibly proud and honored to be named 1 of just 23 winners from over 1,700 proposals submitted to ARPA-H's Sprint for Women's Health program announced today by the White House and First Lady Jill Biden. We are receiving $3M over 2 years that will enable us to advance our lead candidate to IND filing for our first-in-human clinical trial. This innovative therapy addresses bacterial vaginosis, a common but undertreated disease that is associated with serious conditions such as fertility problems and pelvic inflammatory disease. Our solution is a novel bacterial therapy that is immune to predatory viruses and restores the vaginal microbiome to its naturally healthy state. For more information and for links to related materials, visit https://lnkd.in/eV4idYP4

WHAT A BIG DAY! Today at 7:00 am PT we will be talking at the UBS Virtual Organ Restoration and Cell Therapy. 👏 Read the PR below for more information! #regenerativemedicine #celltherapy #hepatx #medicine #startup #innovation #technology #liver

🚨 𝗕𝗥𝗘𝗔𝗞𝗜𝗡𝗚 𝗡𝗘𝗪𝗦! 📣  We are super excited to announce that we have entered into a 𝗹𝗶𝗰𝗲𝗻𝘀𝗲 𝗮𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝗠𝗮𝘆𝗼 𝗖𝗹𝗶𝗻𝗶𝗰 to advance HepaTx’s innovative stem cell technology into clinical trials! 👏  Great time ahead! Read the PR ⬇ https://lnkd.in/eNDMVngV Mayo Clinic Ventures #Technology #startup #celltherapy #liverdisease #Hepatology #regenerativemedicine #innovation

Notable is harnessing our predictive medicine platform to build a pipeline of novel therapeutics. By matching the right drug with the right patient, we aim to increase the clinical response rate of the therapeutics in our pipeline while reducing the risk, time and cost of development. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #flowcytometry, #roboticautomation, #pipeline

We are thrilled to announce the closing of our $4.2M initial funding round. A special thanks to Safar Partners, who led this round, and our other visionary investors who appreciate the tremendous power of our unique approach. We believe that our proprietary tools leveraging the natural function of CRISPR and demystifying the virome will unlock the potential of beneficial bacterial products addressing a broad range of medical and other applications, We are excited about our progress as we embark on this next stage of our growth. For more information see https://lnkd.in/e9gFSkwZ

🚀 Meet Our Advisors! We are excited to highlight that Neil Littman, Founding Partner of Bioverge Ventures and Partner of Riverine Ventures, as one of the esteemed advisors in our #H7 accelerator program. 👉 We are open for application for the 2024 Cohort of H7 Healthcare Accelerator, powered by H7 BioCapital. Early Bird Applications are open until 💥 July 20th 💥! 🦄 Apply for the Program: https://shorturl.at/TfJdB 🦄 Apply to Become Advisor: https://lnkd.in/eSbGpX28  📅 Early Bird Deadline: July 20th, 2024 🎯 About H7 Accelerator Program: https://lnkd.in/g3ycA8eE ------- 🎯Get to know our top-tier accelerator advisor - Neil Littman "Neil Littman, M.S. is Founder & CEO of Bioverge Ventures, a venture capital firm exclusively dedicated to investing in #earlystage, #cuttingedge #healthcare companies. Bioverge’s investment thesis is focused on companies spanning the intersection of health + tech that are utilizing advances in technology to modernize healthcare, from bench-to-bedside." "Previously, Neil was Vice President of Business Development at Notable Labs, an oncology startup and Bioverge portfolio company, where he led the development of global corporate partnerships and contributed to the strategic vision of Notable as part of the Senior Leadership Team. Neil oversaw business development at Notable through the successful completion of the company’s $40 million Series B and was instrumental in negotiating multiple terms sheets to in-license clinical stage oncology assets." 🌷Apply now to learn invaluable insights from Neil Littman get connected with our 100+ industrial leading experts, pitch to top #investors, and scale your #startup! 🥳 Once you're selected for #H7 accelerator cohort, you'll be part of the #H7 community for life. Expand your business and expand your network with access to a talented group of founders, investors, mentors, and industry leaders. #accelerator #venturecapital #fundraising #healthcare #lifesciences #biotech #drugdevelopment #artificialintelligence #medicaldevices #hospitals #clinicaltrials #oncology #research #startup #founders #precisionmedicine #commercialization #sales

Our predictive medicine platform employs advanced technology, including flow cytometry and robotic automation, to bio-simulate treatment of each patient’s cancer at the cellular level. Our biological response database provides improved insight into patient response, helping us to identify promising drugs to develop into new therapeutics. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #flowcytometry, #roboticautomation

Can regular progress updates and reporting with investors make startups more successful? Bioverge Ventures CEO and and venture capitalist, Neil Littman, thinks it could be the case. Here are 4 Reasons why: 📌The Phenomenon of “𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐇𝐲𝐠𝐢𝐞𝐧𝐞” Startups that regularly report to their investors exhibit what's known as "company hygiene." ▶️This means they maintain a disciplined and organized approach to managing their business. In contrast, startups that don't have this practice often lack structure and focus, leading to potential chaos. ▶️Disciplined startups could perform better because they have clear processes and accountability in place. 📌𝐓𝐡𝐞 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐀𝐝𝐯𝐚𝐧𝐭𝐚𝐠𝐞 If a startup hides its challenges, how is it supposed to get the support it needs? ▶️When there’s transparency, everyone wins. ▶️Investors stay informed and startups get to tackle their problems head-on. 📌𝐅𝐨𝐫𝐜𝐞𝐝 𝐑𝐞𝐟𝐥𝐞𝐜𝐭𝐢𝐨𝐧 ▶️Regular reporting forces startups to reflect on their progress. They get to analyze what’s working, what’s not, and identify the challenges ahead. ▶️This self-assessment becomes an opportunity to fine-tune strategies and decisions that would’ve otherwise been overlooked. It introduces a higher degree of intentionality. ▶️It’s a built-in mechanism for continuous improvement. 📌𝐏𝐫𝐨𝐚𝐜𝐭𝐢𝐯𝐞 𝐏𝐫𝐨𝐛𝐥𝐞𝐦-𝐒𝐨𝐥𝐯𝐢𝐧𝐠 ▶️Delaying action until a problem becomes critical is a sure path to disaster. Regular updates mean startups are constantly communicating their challenges and needs. ▶️Small problems get to stay small rather than spiraling out of control. – What do you think? Do startups who report regularly tend to perform better? Share your insights in the comments below 👇🏽 To dive deeper into this, tune into Part 2 of my conversation with Neil Littman: APPLE: https://lnkd.in/gXNPgxHm SPOTIFY: https://lnkd.in/gNtZMVrW  #charmhealthinnovationchallenge #charmhealth #chic

🌱 Pragma Bio is excited to share our latest article "Decoding BGCs: Nature's Blueprint for Tomorrow's Medicines". Ever wondered what are Biosynthetic Gene Clusters (BGCs) and what is their role in medicine? 💊 💉 🤓 Dive into our blog post to explore how these clusters unlock nature's pharmacy, offering potential for groundbreaking drug discovery and far beyond. Join us at Pragma Bio as we navigate BGC exploration for a a better and healthier planet. 🌎 🌍 🌏 #inovation #biotech #BGC #Medicine #DrugDiscovery #biotech #techbio #microbiome #microbiology #syntheticbiology #ai #aiml #smallmolecules